Összesen 2 találat.


001-es BibID:BIBFORM071387
Első szerző:Harangi Mariann (belgyógyász, endokrinológus)
Cím:HDL subfraction distribution and HDL function in untreated dyslipidemic patients / Harangi Mariann, Szentpéteri Anita, Nádró Bíborka, Lőrincz Hajnalka, Seres Ildikó, Páll Dénes, Paragh György
Megjegyzések:Aim: The protective role of high-density lipoprotein (HDL) against atherosclerosis is wellknown. However, both structural and functional changes of the HDL particles may affect itsprotective efficacy. Increased levels of HDL-associated myeloperoxidase (MPO) and decreasedHDL-linked paraoxonase-1 (PON1) activity have been reported in dyslipidemic patients. Somechanges in HDL subfraction distributions were also studied previously, but data on structuraland functional changes in dyslipidemia are not complete. Therefore, the authors aimed toevaluate these qualitative and quantitative markers of HDL in dyslipidemic patients andhealthy control subjects. Methods: Anthropometric parameters, serum levels of lipoproteinsand MPO, as well as PON1 activities were investigated in 81 untreated dyslipidemic patientsand in 32 healthy gender-matched controls. Additionally, HDL subfractions were detectedby an electrophoretic method on polyacrylamide gel (Lipoprint). Results: Significantlyhigher glucose, hemoglobin A1c, total cholesterol, low-density lipoprotein-cholesterol,triglyceride, lipoprotein(a), apolipoprotein B, C-reactive protein, and MPO levels were foundin patients compared to the healthy subjects. There were no significant differences in PON1paraoxonase and arylesterase activities between the two study groups, but MPO/PON1 ratiowas significantly higher in patients. There was a shift towards the smaller HDL subfractions,but only the intermediate HDL ratio was significantly lower in patients compared to controls.Conclusion: The results highlight the importance of HDL-associated pro- and antioxidantenzymes suggesting the possible clinical benefit of MPO/PON1 calculation and confirm thatquantification of HDL-C level alone provides limited data regarding HDL's cardioprotectiveeffect. Calculation of MPO/PON1 ratio may be a useful cardiovascular marker in dyslipidemia.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
high-density lipoprotein
Megjelenés:Vessel Plus. - 1 (2017), p. 166-173. -
További szerzők:Szentpéteri Anita (1988-) (biológus) Nádró Bíborka (1992-) (általános orvos) Lőrincz Hajnalka (1986-) (biológus) Seres Ildikó (1954-) (biokémikus) Páll Dénes (1967-) (belgyógyász, kardiológus) Paragh György (1953-) (belgyógyász)
Pályázati támogatás:GINOP-2.3.2-15-2016-00062
Internet cím:Szerző által megadott URL
Intézményi repozitóriumban (DEA) tárolt változat


001-es BibID:BIBFORM069720
Első szerző:Harangi Mariann (belgyógyász, endokrinológus)
Cím:LDL apheresis or PCSK9 inhibition? Sometimes we have to combine them / Mariann Harangi, Lilla Juhász, Bíborka Nádró, József Balla, György Paragh
Megjegyzések:This study presents the case of a female patient with severe heterozygous familialhypercholesterolemia. Despite the combined maximum dose oral treatment with rosuvastatinand ezetimibe, we found markedly elevated lipid parameters. Therefore, we indicated monthlyselective low density lipoprotein (LDL) apheresis treatment using the Direct Adsorption ofLipoproteins system. After more than 2 years the lipid levels of the patients were still above thetherapeutic goals. Finally, we completed the treatment by the inhibitor evolocumab biweekly.Further LDL cholesterol (LDL-C) reduction was achieved resulting in lipid parameters ongoals. However, administration of evolocumab without LDL apheresis could not reduce theLDL-C below 2.5 mmol/L. We concluded that both LDL apheresis and proprotein convertasesubtilisin/kexin type 9 (PCSK9) inhibitor treatments were effective and well tolerated. None ofthem alone would be enough to achieve lipid goals in this patient. However, the combination ofthese potent treatments may normalize the lipid levels and prevent cardiovascular complications.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
LDL apheresis
PCSK9 inhibition
familial hypercholesterolemia
low-density lipoprotein
Megjelenés:Vessel Plus. - 1 (2017), p. 91-95. -
További szerzők:Juhász Lilla (1990-) (általános orvos) Nádró Bíborka (1992-) (általános orvos) Balla József (1959-) (belgyógyász, nephrológus) Paragh György (1953-) (belgyógyász)
Internet cím:Szerző által megadott URL
Intézményi repozitóriumban (DEA) tárolt változat
Rekordok letöltése1